This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stott, P. Search for Related Content Social Bookmarking                         What's this?

Quality driven management of tablet-treated type 2 diabetes — potential increases in GP practice prescribing costs

Tadworth Medical Centre, Troy Close, Tadworth, Surrey, KT20 5JE, UK, Peter.Stott{at}BTInternet.com

A prospective audit was undertaken to characterise Ametabolic control, risk-factor profiles and costs of pharmaceutical agents required to achieve quality target measures in 100 type 2 diabetic patients attending a diabetic clinic in UK general practice. Despite reasonable glycaemic control, the coronary risk of these patients was high due to age, diabetes and dyslipidaemia. It proved impossible to quantify coronary risk for many older patients exactly since existing scales do not apply to patients aged over 75 years. The extra cost of initiating new treatments to modify coronary heart disease (CHD) risk for an average patient with type 2 diabetes was estimated to be £400—£860 (average £633) per annum. The treatment costs of instituting treatment to achieve quality measures should be considered when new quality standards are introduced. Without this investment the long-term costs of managing the complications of diabetes will be much higher.

Key Words: diabetes • quality • NSF • guidelines • prescribing • costs.

References

• Alberti KG, Gries FA for the European NIDDM Policy Group 1988. Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabet Med 1988;5:275-81.[Web of Science][Medline] [Order article via Infotrieve]
• Diabetes UK. Recommendations for the management of diabetes in primary care; http://www.diabetes.org.uk
• Epsom and St Helier Hospital Trust; local guidelines.
• National Service Framework for Coronary Heart Disease. March 2000. Department of Health. London.
• British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society endorsed by the British Diabetic Association. Joint British recommendations on the prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):S1-S29.[Free Full Text]
• Mead M. Targeting lipids in diabetes. Update 2002;64(9):618-28.
• National Institute for Clinical Excellence. March 2001. Guidance on the use of orlistat for the treatment of obesity in adults. Technology appraisal guidance - No. 22.
• National Institute for Clinical Excellence. October 2001. Guidance on the use of sibutramine for the treatment of obesity in adults. Technology appraisal guidance - No. 31.
• Ramsay LE, Williams B., Johnson GD et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999;319:630-5.[Free Full Text]
• Haffner SM, Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes mellitus and in non-diabetic subjects without prior myocardial infarction. N Engl J Med 1998;339:229-34.[Abstract/Free Full Text]
• Campbell IW, Purcell H. The silent sextet. Br J Diabetes Vasc Dis 2001;1:3-6.[Free Full Text]
• MIMS monthly index of medical specialities. March 2002.
• Bottomley J. Managing care of type 2 diabetes. Learnings from T2ARDIS. Br J Diabetes Vasc Dis 2001;1:68-72.[Abstract/Free Full Text]
• Holmes J., McGill S., Kind P., Bottomley J., Gillam S., Murphy M. Health-related quality of life in type 2 diabetes (T2ARDIS-2). Value in Health 2000;3(S1):S47.[CrossRef]
• UK Prospective Diabetes Study (UKPDS). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
• UK Prospective Diabetes Study (UKPDS). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321: 412-19.[Abstract/Free Full Text]
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 1, 64-68 (2003)
DOI: 10.1177/14746514030030011101


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stott, P. Search for Related Content Social Bookmarking                         What's this?